213 related articles for article (PubMed ID: 30206644)
1. Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review.
Lee J; Yoon WS; Koom WS; Rim CH
Strahlenther Onkol; 2019 Feb; 195(2):93-102. PubMed ID: 30206644
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Gkika E; Hallauer L; Kirste S; Adebahr S; Bartl N; Neeff HP; Fritsch R; Brass V; Nestle U; Grosu AL; Brunner TB
BMC Cancer; 2017 Nov; 17(1):781. PubMed ID: 29162055
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review.
Frakulli R; Buwenge M; Macchia G; Cammelli S; Deodato F; Cilla S; Cellini F; Mattiucci GC; Bisello S; Brandi G; Parisi S; Morganti AG
Br J Radiol; 2019 May; 92(1097):20180688. PubMed ID: 30673295
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
Brunner TB; Blanck O; Lewitzki V; Abbasi-Senger N; Momm F; Riesterer O; Duma MN; Wachter S; Baus W; Gerum S; Guckenberger M; Gkika E
Radiother Oncol; 2019 Mar; 132():42-47. PubMed ID: 30825968
[TBL] [Abstract][Full Text] [Related]
6. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies.
Rim CH; Kim HJ; Seong J
Radiother Oncol; 2019 Feb; 131():135-144. PubMed ID: 30773180
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies.
Goodman KA; Wiegner EA; Maturen KE; Zhang Z; Mo Q; Yang G; Gibbs IC; Fisher GA; Koong AC
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):486-93. PubMed ID: 20350791
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic outcome and related predictors of stereotactic body radiotherapy for small liver-confined HCC: a systematic review and meta-analysis of observational studies.
Long Y; Liang Y; Li S; Guo J; Wang Y; Luo Y; Wu Y
Radiat Oncol; 2021 Apr; 16(1):68. PubMed ID: 33832536
[TBL] [Abstract][Full Text] [Related]
9. Repeated SBRT for in- and out-of-field recurrences in the liver.
Gkika E; Strouthos I; Kirste S; Adebahr S; Schultheiss M; Bettinger D; Fritsch R; Brass V; Maruschke L; Neeff HP; Lang SA; Nestle U; Grosu AL; Brunner TB
Strahlenther Onkol; 2019 Mar; 195(3):246-253. PubMed ID: 30353350
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.
Polistina FA; Guglielmi R; Baiocchi C; Francescon P; Scalchi P; Febbraro A; Costantin G; Ambrosino G
Radiother Oncol; 2011 May; 99(2):120-3. PubMed ID: 21621289
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative radiotherapy for patients with unresectable or medically inoperable cholangiocarcinoma.
Liu MY; Lo CH; Lin CS; Chao HL; Yang JF; Lin KT; Fan CY; Su YF; Huang WY
Tumori; 2017 May; 103(3):236-241. PubMed ID: 28058710
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma.
Barney BM; Olivier KR; Miller RC; Haddock MG
Radiat Oncol; 2012 May; 7():67. PubMed ID: 22553982
[TBL] [Abstract][Full Text] [Related]
13. Reirradiation using stereotactic body radiotherapy in the management of recurrent or second primary head and neck cancer: A meta-analysis and systematic review.
Lee J; Kim WC; Yoon WS; Koom WS; Rim CH
Oral Oncol; 2020 Aug; 107():104757. PubMed ID: 32388412
[TBL] [Abstract][Full Text] [Related]
14. Preliminary experience with CT-guided high-dose rate brachytherapy as an alternative treatment for hepatic recurrence of cholangiocarcinoma.
Kamphues C; Seehofer D; Collettini F; Bahra M; Neuhaus P; Wust P; Denecke T; Gebauer B; Schnapauff D
HPB (Oxford); 2012 Dec; 14(12):791-7. PubMed ID: 23134179
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiotherapy for Centrally Located Primary Non-Small-Cell Lung Cancer: A Meta-Analysis.
Yu T; Shin IS; Yoon WS; Rim CH
Clin Lung Cancer; 2019 Jul; 20(4):e452-e462. PubMed ID: 31029573
[TBL] [Abstract][Full Text] [Related]
16. Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial.
Feng M; Suresh K; Schipper MJ; Bazzi L; Ben-Josef E; Matuszak MM; Parikh ND; Welling TH; Normolle D; Ten Haken RK; Lawrence TS
JAMA Oncol; 2018 Jan; 4(1):40-47. PubMed ID: 28796864
[TBL] [Abstract][Full Text] [Related]
17. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Tse RV; Hawkins M; Lockwood G; Kim JJ; Cummings B; Knox J; Sherman M; Dawson LA
J Clin Oncol; 2008 Feb; 26(4):657-64. PubMed ID: 18172187
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes.
Shanker MD; Moodaley P; Soon W; Liu HY; Lee YY; Pryor DI
J Med Imaging Radiat Oncol; 2021 Dec; 65(7):956-968. PubMed ID: 34396706
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
